Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

SNCAIP anticorps (Internal Region)

SNCAIP Reactivité: Humain WB, IHC Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN350932
  • Antigène Voir toutes SNCAIP Anticorps
    SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))
    Épitope
    • 15
    • 5
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Internal Region
    Reactivité
    • 26
    • 24
    • 17
    Humain
    Hôte
    • 38
    • 2
    Lapin
    Clonalité
    • 39
    • 1
    Polyclonal
    Conjugué
    • 16
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp SNCAIP est non-conjugé
    Application
    • 28
    • 13
    • 13
    • 12
    • 7
    • 4
    • 3
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC)
    Specificité
    Specific for Synphilin-1.
     Réactivité croisée
    Humain
    Réactivité croisée (Details)
    Other species not yet tested.
    Purification
    IgG
    Immunogène
    A synthetic peptide from the internal region of human Synphilin-1 (Synphilin 1, alpha synuclein interacting protein) conjugated to an immunogenic carrier protein was used as the antigen.
    Isotype
    IgG
    Top Product
    Discover our top product SNCAIP Anticorps primaire
  • Indications d'application
    IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.
    Conseil sur la manipulation
    Avoid freeze and thaw cycles.
    Stock
    4 °C/-20 °C
    Stockage commentaire
    Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
    Date de péremption
    12 months
  • Antigène
    SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))
    Autre désignation
    Synphilin-1 (SNCAIP Produits)
    Synonymes
    anticorps sncaip, anticorps MGC88953, anticorps SNCAIP, anticorps LOC100221074, anticorps SYPH1, anticorps Sph1, anticorps Syph1, anticorps 2810407O15Rik, anticorps 4933427B05Rik, anticorps BB104594, anticorps synuclein alpha interacting protein, anticorps synuclein, alpha interacting protein, anticorps synuclein, alpha interacting protein (synphilin), anticorps SNCAIP, anticorps sncaip, anticorps Sncaip
    Sujet
    Tissue specificity: Widely expressed, with highest levels in brain, heart and placenta. Defects in SNCAIP are a cause of Parkinson disease (PD). PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. Constructs encoding portions of SNCA and SNCAIP co-transfected in mammalian cells promote cytosolic inclusions resembling the Lewy bodies of Parkinson disease. Coexpression of SNCA, SNCAIP, and PARK2 result in the formation of Lewy body-like ubiquitin-positive cytosolic inclusions. Familial mutations in PARK2 disrupt the ubiquitination of SNCAIP and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy body-associated proteins and link PARK2 and SNCA in a common pathogenic mechanism through their interaction with SNCAIP.,Neurodegeneration,Alpha-synuclein-interacting protein, SNCAIP
    UniProt
    Q9Y6H5
Vous êtes ici:
Support technique